Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries.
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million; Awakn Life Sciences begins trading on OTCQB; atai Life Sciences creates subsidiary for salvia divinorum derivatives. Read more in Issue 42 of the Psychedelics Newsletter.
Overwhelming majority of Canadians support legalisation of psilocybin; Could psychedelic drugs revolutionise mental healthcare in the UK? Cybin becomes first psychedelic company to list on the New York Stock Exchange. Read more in Issue 41 of the Psychedelics Newsletter
BHMNC Brain Health on precision psychiatry and psychedelics;
Global psychedelics research institute launched in Melbourne with AU$40m in funding; Poll reveals majority of Canadians support legalisation of psilocybin-assisted therapy. Read more in Issue 40 of the Psychedelics Newsletter
Field Trip’s Co-founder and Executive Chairman Ronan Levy on investor opportunities following Nasdaq listing; Cybin to list on NYSE’s Small Cap Market to finance expansion; The Times: Psychedelic firms take a trip over the Atlantic in search of funds. Read more in Issue 39 of the Psychedelics Newsletter.
Biden calls for lower drug prices: should psychedelics investors be concerned? Jamaica adopts protocols for cultivating and possessing psilocybin; Nasdaq explores the growth of the psychedelic industry. Read more in Issue 38 of the Psychedelics Newsletter
Data science driving innovation in psychedelic medicine; Looking back on the PSYCH Investor Summit: Research & Development; atai Life Sciences’ Founder warns decriminalisation could set back regulation. Read more in Issue 37 of the Psychedelics Newsletter.
PSYCH Investor Summit: Research & Development kicks off today; Tryp Therapeutics to treat psychiatric disorders; Braxia Scientific identifies short-term ROI in psychedelic medicine. Read more in Issue 36 of the Psychedelics Newsletter.
One week remains until the PSYCH Investor Summit: Research & Development; Texas legalises medical psychedelic research; Compass Pathways conducts world’s largest psilocybin trial to-date. Read more in Issue 35 of The Psychedelics Newsletter.